ZLB Behring-Sponsored National Hemophilia Foundation Symposia to Address the Needs of the Bleeding Disorders Community.

KING OF PRUSSIA, Pa. -- ZLB Behring (a CSL Limited Company), a global leader in the plasma protein biotherapeutics industry, today announced a series of educational and social event sponsorships at the National Hemophilia Foundation's (NHF) 56th Annual Meeting to be held Nov. 4-6, 2004 in Dallas at the Hyatt Regency at Reunion.

ZLB Behring is sponsoring three industry symposia at the NHF meeting, which are open to the bleeding disorders community. Nurses attending the breakfast symposium, "von Willebrand's Disease (VWD): Overview, Treatment and Experience," will receive continuing education credit. Von Willebrand's Disease is the most common bleeding disorder in women and girls (1% to 2% of the population or, approximately 1.4 to 2.8 million nationwide). VWD, which is genetically transmitted from generation to generation, is caused by a defect or deficiency of an essential blood clotting protein called von Willebrand factor. Details regarding all of the ZLB Behring-sponsored symposia follow:

--"March of Moms: Connections Through Experience," Friday, November 5, 7:00-9:00 AM - Mothers who have sons with hemophilia will share experiences and challenges related to raising their child and taking care of themselves

--"von Willebrand's Disease (VWD): Overview, Treatment and Experience," Saturday, November 6, 7:00-9:00 AM - Topics presented by Tom Abshire, MD will include an overview of VWD, appropriate and timely treatment of bleeds, prophylaxis and surgery. Additionally, a panel of three women with VWD, and who have children with VWD, will discuss key points of Dr. Abshire's presentation by relating their experiences. This program will provide CNE credit

--"Pathways to Choice: There Are Options for Hemophilia B," Saturday, November 6, 7:00-9:00 AM - Jorge DiPaola will present an overview of hemophilia B, history and parameters that should be considered when selecting a product for the treatment of hemophilia B

Armadillo Race Also Planned

ZLB Behring is also sponsoring a unique Von Willebrand's Disease networking event intended to resemble a Texas-style tailgate party. Guests will enter through turnstile gates and will be able to navigate their way through various "zones." The Locker Room zone will include an interactive Trivia Challenge, hosted by an emcee who will pose VWD and treatment-related questions. Another zone will feature an armadillo race where guests can suit up in leather gloves, pick their armadillo and gear them up for a race to the finish line. If this competition is not enough, then guests can participate in the Texas Tailgate Pie Eating Contest.

ZLB Behring's continued support of the bleeding disorders community extends to other organizations, including the U.S. National Hemophilia Foundation's Project Red Flag: Real Talk About Women's Bleeding Disorders. Under the umbrella of this program, grants have been awarded to 12 chapters and associations to stimulate the development of innovative efforts for women affected by bleeding disorders, and to build a body of outreach strategies, evaluation tools and measurable outcomes. A Project Red Flag Reception and a peer education workshop "Woman-to-Woman," will take place on Nov. 5 at the NHF meeting.

Through Project SHARE (Supplying Hemophilia Aid and Relief Everywhere), the World Federation of Hemophilia (WFH) and the ZLB Behring Patient Assistance Program, ZLB Behring recently donated hemophilia therapy products for distribution in developing countries and in the United States. The donated products total over 15.2 million units and represent an approximate market value of US$9.8 million. Product donations through the ZLB Behring Patient Assistance Program provide medically necessary therapy to patients who are uninsured, underinsured, or who cannot afford their prescribed therapy throughout the United States.

About ZLB Behring

ZLB Behring is a global leader in the plasma protein biotherapeutics industry. Dedicated to improving the quality of life for patients throughout the world, ZLB Behring provides safe and effective plasma-derived and recombinant products and offers patients a wide range of related services. The company's broad portfolio of life-saving therapeutics are used in the treatment of individuals with hemophilia and other bleeding disorders, immune deficiency disorders and inherited emphysema; the prevention of hemolytic diseases for the newborn; cardiac surgery patients; and shock and burn victims. Additionally, ZLB Behring operates one of the world's largest, fully-owned plasma collection networks. ZLB Behring is a subsidiary of CSL Limited, a bio-pharmaceutical company, which operates worldwide from its headquarters in Melbourne, Australia.